Cite
HARVARD Citation
Barr, P. et al. (2022). Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma. Leukemia & lymphoma. 63 (7), pp. 1728-1732. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Barr, P. et al. (2022). Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma. Leukemia & lymphoma. 63 (7), pp. 1728-1732. [Online].